Cancer Center Support Grant

总体来说 项目摘要/摘要！ 作为NCI指定的综合癌症中心，耶鲁大学癌症中心(YCC)现已进入第43个年头 建立了高影响力的癌症研究的强大传统和深厚的沟通和 将代表所有生物医学的286名基础、翻译、人群和临床科学家联合起来的协作 纪律。YCC为这些调查人员配备了一套支持核心和强大的协作 机遇和资源。通过方案内和方案间的协作， YCC是为了了解和预防癌症，及早发现癌症，并更多地管理癌症治疗 准确有效。这七个研究项目是YCC的核心，每个项目都由一名 基础科学家与临床/翻译科学家合作，以促进跨学科研究和 耶鲁大学科学从替补席到临床的进步。此外，YCC还支持和管理共享 提供独特的专业知识和支持技术的资源，以丰富范围并加快 每项研究计划的进展情况。YCC基础设施进一步实现了开创性的临床试验 利用耶鲁大学的科学知识，结合新的设计和生物标记物评估来优化患者 选择，定义治疗耐药性，并提供新的治疗方法。总体癌症资助(直接 成本)从2012年的5820万美元增加到2017年的8800万美元，增幅为51%，其中包括从1780万美元增加到2350万美元 在NCI资金(直接成本)中。YCC拥有两个NCI孢子赠款，一个UM1，U10，多个P01，许多多- 调查员R01奖励，并在两个SU2C梦之队奖中发挥领导作用。此外，在当前的 在资金周期内，YCC举债590万美元，反映CCSG发展资金和机构支持，以 推进新的研究和合作，获得5560万美元的新外部资金-9倍于 投资。在同一时期，介入治疗试验的应计利润增加了82%，从471项增加到859项， 早期治疗试验(Pilot，I，I-II)的应计收益增加了三倍，现在占总数的44% 治疗应计费用。同样重要的是，YCC扩大并投资于旨在 在个人、机构和政策层面影响癌症不平等和我们集水区的需求。 在未来五年，YCC将继续开发促进创新的举措和资源， 协作、卓越和协同，以最大限度地发挥耶鲁的才华和专业知识对 了解、预防和治疗癌症。

OVERALL PROJECT SUMMARY/ABSTRACT! Now in its 43rd year as an NCI-Designated Comprehensive Cancer Center, Yale Cancer Center (YCC) has established a strong tradition of high-impact cancer research and a deep culture of communication and collaboration that unites 286 basic, translational, population, and clinical scientists representing all biomedical disciplines. YCC arms these investigators with a suite of enabling cores and powerful collaborative opportunities and resources. Through intra- and inter-programmatic collaboration, the overarching goals of YCC are to understand and prevent cancer, detect cancer early, and manage cancer treatment more accurately and effectively. The seven Research Programs are the heart of YCC, and each program is led by a basic scientist in partnership with a clinical/translational scientist to foster transdisciplinary research and the advancement of Yale science from the bench to the clinic. In addition, YCC supports and manages Shared Resources that provide unique expertise and enabling technologies that enrich the scope and expedite progress of each Research Program. YCC infrastructure further enables ground-breaking clinical trials that capitalize on Yale science and incorporate novel designs and biomarker assessments to optimize patient selection, define treatment resistance, and inform new therapeutic approaches. Overall cancer funding (direct costs) has increased 51% from $58.2M in 2012 to $88M in 2017, including an increase from $17.8M to $23.5M in NCI funding (direct costs). YCC holds two NCI SPORE grants, a UM1, U10, multiple P01s, numerous multi- investigator R01 grants, and leadership in two SU2C Dream Team awards. Additionally, during the current funding cycle, YCC leveraged $5.9M, reflecting CCSG Developmental Funds and institutional support, to advance new research and collaborations, resulting in $55.6M in new extramural funding - a 9-fold return on investment. During the same period, accrual to interventional treatment trials increased 82%, from 471 to 859, and accruals to early-phase treatment trials (pilot, I, I-II) increased three-fold, now representing 44% of total treatment accruals. No less important, YCC has expanded and invested in initiatives and research that seeks to impact cancer inequities and the needs of our catchment area at an individual, institutional, and policy level. Over the next five years, YCC will continue to develop initiatives and resources to foster innovation, collaboration, excellence and synergy to maximize the impact of Yale’s talent and expertise on the understanding, prevention and treatment of cancer.!